Fiscal Year 2025 KEY HIGHLIGHTS$272.1M net revenue$194.7M adj. gross profit$16.1M Adj. Ebitda Results Events Latest Event Waldencast plc First Quarter Fiscal 2025 Earnings Call May 14, 2025 8:30 AM EDT Latest Event Waldencast plc Fourth Quarter Fiscal 2024 Earnings Call March 19, 2025 8:30 AM EDT All Events Press Releases Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel June 15, 2026 Waldencast Announces Sale of Obagi Medical to Bridgepoint June 1, 2026 All Press Releases Stock Chart Stock Information Minimum 15 minutes delayed. Source: LSEG
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel June 15, 2026